Cargando…

Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma

Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in regions of equatorial Africa where P. falciparum malaria is holoendemic. The tumor is consistently associated with Epstein-Barr virus (EBV). Screening for EBV DNA in plasma in a high-risk population in Hong Kong has been shown to...

Descripción completa

Detalles Bibliográficos
Autores principales: Xian, Rena R., Kinyera, Tobias, Otim, Isaac, Sampson, Joshua N., Nabalende, Hadijah, Legason, Ismail D., Stone, Jennifer, Ogwang, Martin D., Reynolds, Steven J., Kerchan, Patrick, Bhatia, Kishor, Goedert, James J., Mbulaiteye, Sam M., Ambinder, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713969/
https://www.ncbi.nlm.nih.gov/pubmed/34970500
http://dx.doi.org/10.3389/fonc.2021.804083
_version_ 1784623821982007296
author Xian, Rena R.
Kinyera, Tobias
Otim, Isaac
Sampson, Joshua N.
Nabalende, Hadijah
Legason, Ismail D.
Stone, Jennifer
Ogwang, Martin D.
Reynolds, Steven J.
Kerchan, Patrick
Bhatia, Kishor
Goedert, James J.
Mbulaiteye, Sam M.
Ambinder, Richard F.
author_facet Xian, Rena R.
Kinyera, Tobias
Otim, Isaac
Sampson, Joshua N.
Nabalende, Hadijah
Legason, Ismail D.
Stone, Jennifer
Ogwang, Martin D.
Reynolds, Steven J.
Kerchan, Patrick
Bhatia, Kishor
Goedert, James J.
Mbulaiteye, Sam M.
Ambinder, Richard F.
author_sort Xian, Rena R.
collection PubMed
description Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in regions of equatorial Africa where P. falciparum malaria is holoendemic. The tumor is consistently associated with Epstein-Barr virus (EBV). Screening for EBV DNA in plasma in a high-risk population in Hong Kong has been shown to be useful in facilitating the early diagnosis of nasopharyngeal carcinoma, another EBV-associated tumor. Here, we investigate plasma EBV as a diagnostic marker for eBL in children in Uganda. We studied plasma specimens from 25 children with eBL and 25 controls matched for age (<3-16 years), gender and geography, including many with asymptomatic P. falciparum infection. These specimens were previously collected under the auspices of the EMBLEM (Epidemiology of Burkitt lymphoma in East African children and minors) study. After cell-free DNA isolation, plasma EBV DNA was measured using a quantitative PCR assay that amplifies the large internal repeats of the EBV genome. All children with eBL had measurable plasma EBV, as compared to 84% of control children. The median plasma EBV DNA level was 5.23 log(10) copies/mL (interquartile range 3.54-6.08 log(10) copies/mL) in children with eBL. In contrast, the median plasma EBV DNA level was 0.37 log(10) copies/mL (interquartile range 0.18-1.05 log(10) copies/mL) in children without lymphoma. An EBV threshold of 2.52 log(10) copies/mL yielded a sensitivity of.88 and a specificity of 1. The estimated AUC was 0.936 (95% CI: 0.8496 – 1.00) for the corresponding ROC curve. Plasma EBV copy number did not depend on age, gender, or malaria screening status. However, two control children with asymptomatic P. falciparum infection and parasitemia also had high plasma EBV copy number. Our analysis suggests that measurements of EBV copy number in plasma may be useful in identifying children with eBL versus control children. A promising area for future research is the differentiation of high copy number associated with tumor versus high copy number associated with asymptomatic parasitemia.
format Online
Article
Text
id pubmed-8713969
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87139692021-12-29 Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma Xian, Rena R. Kinyera, Tobias Otim, Isaac Sampson, Joshua N. Nabalende, Hadijah Legason, Ismail D. Stone, Jennifer Ogwang, Martin D. Reynolds, Steven J. Kerchan, Patrick Bhatia, Kishor Goedert, James J. Mbulaiteye, Sam M. Ambinder, Richard F. Front Oncol Oncology Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in regions of equatorial Africa where P. falciparum malaria is holoendemic. The tumor is consistently associated with Epstein-Barr virus (EBV). Screening for EBV DNA in plasma in a high-risk population in Hong Kong has been shown to be useful in facilitating the early diagnosis of nasopharyngeal carcinoma, another EBV-associated tumor. Here, we investigate plasma EBV as a diagnostic marker for eBL in children in Uganda. We studied plasma specimens from 25 children with eBL and 25 controls matched for age (<3-16 years), gender and geography, including many with asymptomatic P. falciparum infection. These specimens were previously collected under the auspices of the EMBLEM (Epidemiology of Burkitt lymphoma in East African children and minors) study. After cell-free DNA isolation, plasma EBV DNA was measured using a quantitative PCR assay that amplifies the large internal repeats of the EBV genome. All children with eBL had measurable plasma EBV, as compared to 84% of control children. The median plasma EBV DNA level was 5.23 log(10) copies/mL (interquartile range 3.54-6.08 log(10) copies/mL) in children with eBL. In contrast, the median plasma EBV DNA level was 0.37 log(10) copies/mL (interquartile range 0.18-1.05 log(10) copies/mL) in children without lymphoma. An EBV threshold of 2.52 log(10) copies/mL yielded a sensitivity of.88 and a specificity of 1. The estimated AUC was 0.936 (95% CI: 0.8496 – 1.00) for the corresponding ROC curve. Plasma EBV copy number did not depend on age, gender, or malaria screening status. However, two control children with asymptomatic P. falciparum infection and parasitemia also had high plasma EBV copy number. Our analysis suggests that measurements of EBV copy number in plasma may be useful in identifying children with eBL versus control children. A promising area for future research is the differentiation of high copy number associated with tumor versus high copy number associated with asymptomatic parasitemia. Frontiers Media S.A. 2021-12-14 /pmc/articles/PMC8713969/ /pubmed/34970500 http://dx.doi.org/10.3389/fonc.2021.804083 Text en Copyright © 2021 Xian, Kinyera, Otim, Sampson, Nabalende, Legason, Stone, Ogwang, Reynolds, Kerchan, Bhatia, Goedert, Mbulaiteye and Ambinder https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xian, Rena R.
Kinyera, Tobias
Otim, Isaac
Sampson, Joshua N.
Nabalende, Hadijah
Legason, Ismail D.
Stone, Jennifer
Ogwang, Martin D.
Reynolds, Steven J.
Kerchan, Patrick
Bhatia, Kishor
Goedert, James J.
Mbulaiteye, Sam M.
Ambinder, Richard F.
Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title_full Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title_fullStr Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title_full_unstemmed Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title_short Plasma EBV DNA: A Promising Diagnostic Marker for Endemic Burkitt Lymphoma
title_sort plasma ebv dna: a promising diagnostic marker for endemic burkitt lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713969/
https://www.ncbi.nlm.nih.gov/pubmed/34970500
http://dx.doi.org/10.3389/fonc.2021.804083
work_keys_str_mv AT xianrenar plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT kinyeratobias plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT otimisaac plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT sampsonjoshuan plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT nabalendehadijah plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT legasonismaild plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT stonejennifer plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT ogwangmartind plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT reynoldsstevenj plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT kerchanpatrick plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT bhatiakishor plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT goedertjamesj plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT mbulaiteyesamm plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma
AT ambinderrichardf plasmaebvdnaapromisingdiagnosticmarkerforendemicburkittlymphoma